S&P Adds Martek to Its Top 10 List

The biotech outfit replaces car-parts retailer AutoZone in the portfolio of S&P's best investment ideas

On May 13, Standard & Poor's equity research group made changes to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. Martek Biosciences (MATK ), a maker of nutritional supplements and food ingredients, has been tapped to replace auto-products chain AutoZone (AZO ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.